Lyophilized drugs refer to freeze-dried drugs that have longer shelf life and stability. They provide convenience in transportation and minimize risk of contamination as compared to liquid formulations. Lyophilized drugs are preferred over liquid formulations for biological drugs owing to their complex nature and complex manufacturing process. The increasing demand for lyophilization of monoclonal antibodies, vaccines, and other complex biological molecules is driving the growth of lyophilized drugs market.
The global Lyophilized Drugs Market is estimated to be valued at Us$ 317.8 Bn in 2023 and is expected to exhibit a CAGR Of 13% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends driving the lyophilized drugs market is increased adoption of lyophilization for complex biological drugs. The introduction of advanced lyophilization technologies has enabled pharmaceutical manufacturers to effectively lyophilize complex drugs such as monoclonal antibodies and vaccines that were previously considered challenging to freeze-dry. Advantages such as long shelf life, stability at ambient temperature, and reduced logistical costs associated with transportation of lyophilized drugs are boosting their adoption for biological drugs. It is estimated that over 500 monoclonal antibodies are currently in clinical trials, which will further drive the demand for lyophilization technologies and services. Increased focus on development of advanced lyophilization techniques tailored for complex drugs will continue to propel the lyophilized drugs market during the forecast period.
Segment Analysis
Lyophilized Drugs Market is dominated by the lyophilized injectables segment which holds around 60% share of the total market. Lyophilized injectables are preferred over conventional liquid injectables due to better stability, longer shelf life and ease of transport and storage without refrigeration. Being heat and moisture stable, lyophilized injectables can withstand harsh climatic conditions and do not require cold chain transportation. This makes them ideal for use in developing regions and remote areas with limited cold chain infrastructure.
Key Takeaways
The Global Lyophilized Drugs Market Size is expected to witness high growth during the forecast period of 2023 to 2030. The market size for 2023 is US$ 317.8 Bn.
Regional analysis:
North America currently dominates the lyophilized drugs market owing to high adoption of advanced lyophilization technologies and growing demand for vaccines& biologics in the region. However, Asia Pacific is expected to grow at the fastest pace during the forecast period owing to improving healthcare infrastructure and increasing investments by pharmaceutical companies in developing markets like India,China.
Key players:
Key players operating in the Lyophilized Drugs market are Gilead Sciences, Inc, Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Cipla Limited, Novo Nordisk A/S,SFresenius SE & Co. KGaA (Fresenius Kabi), anofi,Aurobindo Pharmaceuticals, Merck & Co., Inc,Takeda Pharmaceutical Company Limited, Zydus Group,Vetter Pharma,Johnson & Johnson Services, Inc. Gilead Sciences dominates the market for lyophilized drugs with its wide offering of lyophilized HIV drugs while Roche leads the market for lyophilized biologics and antibodies. These top players are focusing on capacity expansion and new product launches to strengthen their market position.
Get more insights on this topic:
